Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | GART | P22102 | 1/20 | 0.40 |
| ▸ | ATIC | P31939 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22223308 | 0.96 | GLP1R (0.56) | GLP1RPTGS1PTGS2FOLH1GLO1 | |
| SCHEMBL20496415 | 0.92 | GLP1R (0.56) | GLP1RPTGS1PTGS2FOLH1GLO1 | |
| SCHEMBL3502650 | 0.92 | GLP1R (0.56) | GLP1RPTGS1PTGS2FOLH1GLO1 | |
| SCHEMBL3501908 | 0.92 | GLP1R (0.56) | GLP1RPTGS1PTGS2FOLH1GLO1 | |
| SCHEMBL20496414 | 0.92 | GLP1R (0.56) | GLP1RPTGS1PTGS2FOLH1GLO1 | |
| SCHEMBL29548162 | 0.90 | GLP1R (0.48) | GLP1RPTGS1PTGS2FOLH1HPGD | |
| SCHEMBL22223483 | 0.88 | PTGS1 (0.51) | GLP1RPTGS1PTGS2FOLH1GLO1 | |
| SCHEMBL22311640 | 0.87 | FOLH1 (0.44) | GLP1RFOLH1 | |
| SCHEMBL22311946 | 0.87 | FOLH1 (0.44) | GLP1RFOLH1 | |
| SCHEMBL19903763 | 0.87 | FOLH1 (0.44) | GLP1RFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | GLP1R 2800/4885PTGS1 1489/4885PTGS2 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.